Comparative Pharmacology
Head-to-head clinical analysis: ACLOVATE versus CLOBETASOL PROPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACLOVATE versus CLOBETASOL PROPIONATE.
ACLOVATE vs CLOBETASOL PROPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines and suppression of immune response via modulation of gene expression.
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
Apply topically as a thin film to affected areas once to twice daily. Maximum 50 g/week. Treatment duration not to exceed 2 consecutive weeks.
None Documented
None Documented
Clinical Note
moderateClobetasol propionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Gatifloxacin."
Clinical Note
moderateClobetasol propionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rosoxacin."
Clinical Note
moderateClobetasol propionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Terminal elimination half-life is approximately 2-3 hours after topical application. However, due to prolonged cutaneous retention, clinical effects may persist beyond systemic elimination.
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Primarily fecal (biliary) with minimal renal excretion. Less than 5% of a topical dose is recovered in urine as metabolites; the majority is eliminated via feces after hepatic metabolism.
Category C
Category A/B
Topical Corticosteroid
Topical Corticosteroid
Clobetasol propionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Trovafloxacin."